Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
Provided By GlobeNewswire
Last update: Aug 28, 2025
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.
Read more at globenewswire.com
